Gabapentin

GPTKB entity

Statements (51)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:approves gptkb:1993
gptkbp:atccode N03 AX12
gptkbp:brand gptkb:Neurontin
gptkbp:category gptkb:C
gptkbp:chemical_formula C9 H17 N1 O2
gptkbp:class gptkb:Antihero
gptkbp:condition gptkb:restless_legs_syndrome
bipolar disorder
fibromyalgia
postherpetic neuralgia
migraine prevention
gptkbp:contraindication hypersensitivity
severe renal impairment
gptkbp:developed_by gptkb:Parke-Davis
gptkbp:dosage_form 300 mg to 600 mg daily
gptkbp:excretion urine
gptkbp:form gptkb:tablet
gptkb:capsule
oral solution
https://www.w3.org/2000/01/rdf-schema#label Gabapentin
gptkbp:interacts_with antacids
opioids
gptkbp:legal_status prescription only
gptkbp:lifespan 5 to 7 hours
gptkbp:mechanism_of_action gptkb:blockade
gptkbp:metabolism renal
gptkbp:related_products gptkb:Pregabalin
gptkb:Vigabatrin
gptkbp:research gptkb:multiple_sclerosis
chronic pain
sleep disorders
ADHD
anxiety treatment
tinnitus
autism spectrum disorder
diabetic neuropathy
cancer pain
alcohol withdrawal
neuropathic itch
gptkbp:route_of_administration oral
gptkbp:side_effect dizziness
fatigue
nausea
swelling
drowsiness
gptkbp:used_for seizures
anxiety disorders
neuropathic pain
gptkbp:bfsParent gptkb:Searle_Pharmaceuticals
gptkbp:bfsLayer 5